



FOR IMMEDIATE RELEASE

Media Contact:

Rx Communications Group, LLC
Eric Goldman
Vice President, Public Relations
917-322-2563
egoldman@rxir.com

**Omthera Pharmaceuticals, Inc. To Present at the 22nd Annual
Piper Jaffray Health Care Conference**

Bedminster, NJ, November 23, 2010 – Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced that Jerry Wisler, President and Chief Executive Officer, will present at the 22nd Annual Piper Jaffray Health Care Conference, being held at The New York Palace hotel in New York City, on Wednesday, December 1, 2010 at 12:30 p.m. Eastern Time.

About Omthera Pharmaceuticals, Inc.

Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately-held emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease. The lead product candidate is Epanova™, an Omega 3 fatty acid compound in Phase III clinical development as a triglyceride-lowering adjunct therapy to diet in patients with very high triglycerides (≥ 500 mg/dL). Omthera is conducting a pivotal Phase III study of Epanova in patients with very high triglycerides under a Special Protocol Assessment (SPA). Future planned clinical trials for Epanova include patients with high triglycerides (≥ 200 mg/dL and ≤ 500 mg/dL) currently on statin therapy. Omthera holds worldwide rights to Epanova. For more information, please visit www.omthera.com.

###